MAP2K7 and melanoma: Over the past decade, innovative systemic therapies, including MAPK pathway inhibitors (BRAF and MEK) and immune checkpoint blockers (cytotoxic T-lymphocyte associated protein 4 and programmed cell death protein 1), have notably improved melanoma prognosis, with 3-year overall survival rates reaching 41.3 and 58.4%, respectively.